Azeliragon - vTv Therapeutics

Drug Profile

Azeliragon - vTv Therapeutics

Alternative Names: PF-04494700; PF-4494700; TTP-488

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransTech Pharma
  • Developer Pfizer; TransTech Pharma; vTv Therapeutics LLC
  • Class Antidementias; Diethylamines; Imidazoles; Small molecules
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists; Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 12 Jun 2018 Updated efficacy data from the STEADFAST phase III trial in Alzheimer’s disease released by vTv Therapeutics
  • 15 May 2018 Efficacy data from the STEADFAST phase III trial in Alzheimer’s disease released by vTv Therapeutics
  • 09 May 2018 vTv Therapeutics terminates the phase III STEADFAST trial based on the subpopulation data analyses from the part A study and the prior azeliragon trials in Alzheimer's disease (Treatment-experienced) in USA, Canada, United Kingdom, Ireland, Australia, New Zealand and South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top